Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Open label evaluation of cannabidiol in dystonic movement disorders
International Journal of Neuroscience, Volume 30, No. 4, Year 1986
Notification
URL copied to clipboard!
Description
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20 to 50% Side-effects of CBD were mild and included hypotension, dry mouth, psychomotor slowing, lightheadedness, and sedation. In 2 patients with coexisting Parkinsonian features, CBD at doses over 300 mg/day exacerbated the hypokinesia and resting tremor. CBD appears to have antidystonic and Parkinsonism-aggravating effects in humans. © 1986 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
Authors & Co-Authors
Consroe, Paul F.
United States, Tucson
Banner - University Medical Center Tucson
Sandyk, Reuven R.
United States, Tucson
Banner - University Medical Center Tucson
Statistics
Citations: 133
Authors: 2
Affiliations: 1
Identifiers
Doi:
10.3109/00207458608985678
ISSN:
00207454
Research Areas
Health System And Policy
Substance Abuse